parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in cardiomyocytes	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 9	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 14495

ZBED5 in dopamine neurons, braak+0.00 (p 1.000) → +0.35 (p 0.360)receipt 14503
ZBED5 in oligodendrocytes, braak+0.04 (p 0.924) → -0.21 (p 0.586)receipt 14502

receipt 14503: ZBED5 in dopamine neurons, braak

power: full sample +0.25 (p 0.323, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.27 (p 0.281, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.33 (p 0.182, n 18). could be the mix.
skeptic: leave-one-out range +0.16 to +0.35, sign flips 0; without severely affected donors +0.25 (p 0.323, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZBED5 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14502: ZBED5 in oligodendrocytes, braak

power: full sample -0.02 (p 0.928, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.03 (p 0.901, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.09 (p 0.709, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.10, sign flips 7; without severely affected donors -0.02 (p 0.928, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZBED5 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts